Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Receives Average Rating of “Buy” from Brokerages

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) has earned a consensus rating of “Buy” from the seven ratings firms that are presently covering the stock, Marketbeat Ratings reports. Seven investment analysts have rated the stock with a buy recommendation. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $31.14.

CPRX has been the subject of several analyst reports. Stephens began coverage on Catalyst Pharmaceuticals in a research note on Monday, November 18th. They issued an “overweight” rating and a $35.00 target price for the company. HC Wainwright restated a “buy” rating and issued a $30.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Friday, November 8th. StockNews.com raised shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday, January 3rd. Finally, Truist Financial raised their price target on shares of Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the company a “buy” rating in a report on Monday, November 11th.

Insiders Place Their Bets

In other news, insider Steve Miller sold 50,000 shares of the stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $21.93, for a total transaction of $1,096,500.00. Following the transaction, the insider now directly owns 686,996 shares in the company, valued at approximately $15,065,822.28. This represents a 6.78 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Gary Ingenito sold 12,000 shares of the firm’s stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $22.72, for a total value of $272,640.00. Following the transaction, the insider now directly owns 51,391 shares in the company, valued at approximately $1,167,603.52. This represents a 18.93 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 79,500 shares of company stock valued at $1,754,140 in the last quarter. Corporate insiders own 11.00% of the company’s stock.

Institutional Investors Weigh In On Catalyst Pharmaceuticals

A number of institutional investors have recently made changes to their positions in CPRX. GAMMA Investing LLC raised its position in Catalyst Pharmaceuticals by 62.1% in the 3rd quarter. GAMMA Investing LLC now owns 1,778 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 681 shares during the period. nVerses Capital LLC bought a new position in shares of Catalyst Pharmaceuticals during the third quarter valued at about $50,000. Larson Financial Group LLC increased its holdings in shares of Catalyst Pharmaceuticals by 27,218.2% in the third quarter. Larson Financial Group LLC now owns 3,005 shares of the biopharmaceutical company’s stock worth $60,000 after buying an additional 2,994 shares during the period. Meeder Asset Management Inc. bought a new stake in shares of Catalyst Pharmaceuticals in the 2nd quarter valued at about $70,000. Finally, Quantbot Technologies LP purchased a new stake in Catalyst Pharmaceuticals during the 3rd quarter valued at about $151,000. Hedge funds and other institutional investors own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Price Performance

Catalyst Pharmaceuticals stock opened at $19.53 on Wednesday. Catalyst Pharmaceuticals has a one year low of $13.12 and a one year high of $24.27. The firm has a market capitalization of $2.33 billion, a P/E ratio of 16.55, a PEG ratio of 3.35 and a beta of 0.79. The business has a fifty day moving average price of $21.72 and a 200-day moving average price of $19.86.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.